Biomedical subjects

S Pungpak

Publications and source records attributed to S Pungpak.

29 records · Page 2Linked to original sources

PubMed1988

Opisthorchis viverrini eggs and adult flukes as nidus and composition of gallstones.

Three cases of opisthorchiasis with calculous cholecystitis was presented. The diagnosis of gallstones was made before praziquantel therapy in 2 cases, and 4 years after treatment in one case. The patients underwent cholecystectomy. Numerous O. viverrini eggs and one dead fluke were found in the bile in one case. A single stone was recovered from each gallbladder. All stones contained O. viverrini eggs. Fragments of flukes were also present in two cases. The stones consisted of a mixture of bilirubin pigment and calcium salts.

Adult↗

PubMed1988

Glucose-6-phosphate dehydrogenase deficiency in Thailand: the influence on the clinical presentation of malaria in male adult patients.

One hundred and ninety-two male malaria patients admitted to two different hospitals within 1 year, were studied. There were 74 malaria cases with glucose-6-phosphate dehydrogenase (G-6-PD) deficiency and 118 G-6-PD normal malaria cases, randomly selected as a control group. History of dark urine, and the presence of jaundice, haematocrit, total bilirubin and parasite count on day of admission were not significantly different comparing both groups. The number of observed complications did not differ either. Distinctions were detected in abnormal symptoms and in some laboratory parameters in patients with Plasmodium falciparum infection. G-6-PD deficient patients had significantly less gastrointestinal disturbances (P = 0.006), higher serum glutamic oxalacetic transaminase (P = 0.009) and significantly lower blood urea nitrogen (P = 0.007) when compared with the control group. These findings indicate that G-6-PD deficiency when the variants are aggregated, in male adult patients has no significant influence on the clinical presentation of malaria.

Adult↗

PubMed1987

Albendazole in the treatment of strongyloidiasis.

Albendazole was used to treat 30 patients with Strongyloides stercoralis infections. There were 21 males and 9 females, 13 to 68 years of age, who were divided into two groups of 11 and 19, respectively. Repeated pre- and post-treatment stool examinations were done by simple direct smear and formalin-ether concentration, and larval quantitations were done by the Stoll and Sasa's technique. Group I patients were given albendazole in dosages of 400 mg/day in divided doses for 3 days. Group II patients were given similar dosages, but were treated again 7 days later on the same schedule. Patients in Group I were followed for 14 days and those in Group II for 30 days. The cure rates were 73% for Group I and 100% for Group II. Side effects were minimal and transient. Albendazole is recommended for the treatment of strongyloidiasis in dosages of 400 mg/day in divided doses for 3 days with treatment repeated one week later.

Adolescent↗

PubMed1985

Studies on the chemotherapy of human opisthorchiasis: effective dose of praziquantel in heavy infection.

Ninety-six patients who had heavy Opisthorchis viverrini infection were studied. Egg count per gram of faeces ranged from 10,800 to 139,000 (mean 26,044.3). Praziquantel 50 mg per kg body weight was given after a morning meal. 68 patients completed the follow up period of 60 days. The cure rate was 97.0%. The side-effects occurred in 61 patients (89.7%). The common side effects were diarrhoea, dizziness, sleepiness, epigastric pain, headache, nausea and anorexia. These side-effects were mild and transient. 62 patients (91.2%) showed clinical improvement, and 20 patients were symptom free on day 60.

Adult↗

PubMed1985

Clinical features in severe opisthorchiasis viverrini.

Clinical features of severe opisthorchiasis were studied in 88 patients. The ratio of males to females was 6.3 : 1; 75% were over 40 years old. The presenting symptoms were obstructive jaundice, 25% associated with secondary infection of biliary system; cholangitis and cholecystitis; intraabdominal mass, which was enlarged liver; 18% had palpable gallbladder; 18% had adenocarcinoma of the bile duct. High bilirubin was found in 46% of cases, high alkaline phosphatase in 80%; elevation of serum transaminase in 78% and low serum albumin in 62% of patients. There was no correlation between severity of the disease and the faecal egg output. The obstructive jaundice patients had low or no egg output. Two patients had no eggs in stool, but numerous Opisthorchis viverrini eggs and flukes were found in the gallbladder and bile ducts at operation.

Adult↗

PubMed1983

Clinical and laboratory evaluation of praziquantel in opisthorchiasis.

A total of 122 patients were treated with a single dose of praziquantel 40 mg per kilogramme body weight, with 96 patients completing the follow up period of 60 days. The parasitological cure rate was 95.8% by single faecal examination. These patients had mild clinical manifestations. The hematological, biochemical and the liver function tests were within the normal limits. High eosinophilia was observed in 84.5% but there were no significant difference after eradication of the flukes. No significant changes were observed in the laboratory investigation at day 60 post treatment.

Adolescent↗

PubMedDate not supplied

Tumour markers in the detection of opisthorchiasis-associated cholangiocarcinoma.

Opisthorchiasis is a major public health problem in north-east Thailand, where over 7 million inhabitants are reported to be infected. A significant percentage of infected individuals develops cholangiocarcinoma terminally, which is rapidly fatal. To determine whether certain tumour markers are elevated in Thai patients with cholangiocarcinoma, and thus might be useful in the diagnosis of cholangiocarcinoma associated with opisthorchiasis in Thailand, the tumour markers CA125 and CA19-9 were measured by radioimmunoassay in 94 serum samples. The subjects consisted of 52 patients admitted for non-gastroenterological diseases, 7 patients with histologically proven cholangiocarcinoma, 7 patients with clinically suspected cholangiocarcinoma, and 28 patients with uncomplicated opisthorchiasis. The mean levels (+/- standard deviation [SD]) of CA19-9 and CA125 in the controls were 12.5 +/- 10.2 and 24.7 +/- 11.1 units/ml respectively. Using the mean + 3SD as the cut-off level, 57.1% of patients with confirmed cholangiocarcinoma had elevated CA19-9 and 28.6% had elevated CA125. In patients with clinically suspected cholangiocarcinoma, 71.4% had elevated CA19-9 and 28.6% had elevated CA125. Among opisthorchiasis patients, 3.6% had elevated CA125 and none had elevated CA19-9. 1.9% of controls had elevated CA19-9 and none had elevated CA125. When positivity of either CA125 or CA19-9 was used as an indicator of malignancy, the sensitivity and specificity of the combined tests reached 85.7% and 98.1% respectively. These preliminary results suggest that the measurement of CA125 and CA19-9 may be useful in the early detection of opisthorchiasis-associated cholangiocarcinoma.

Adenoma, Bile Duct↗

PubMedDate not supplied

Opisthorchis viverrini infection in Thailand: symptoms and signs of infection--a population-based study.

A population-based study of the clinical, laboratory and ultrasonographic findings in patients suffering from mild or moderate opisthorchiasis in Prachinburi province, Thailand was conducted in 1990-1992. The effectiveness of treatment with praziquantel at 40 mg/kg body weight was evaluated. After treatment, a long-lasting, marked improvement in the well-being of the study group was observed. Symptoms common in opisthorchiasis infection decreased in intensity and the clinical response showed total or partial remission in 98% of all cases studied. Total and direct bilirubin concentrations decreased significantly and remained low up to the end of the follow-up period of 2 years, indicating a reduction in cholestasis. Also, white blood cell counts decreased initially, which can be interpreted as a reduction in inflammation intensity. No relationship was found between intensity of infection and age or clinical findings. Population-based treatment of opisthorchiasis appears to have had a significant impact on public health in north-east Thailand. However, it is also evident that drug therapy alone will not solve the opisthorchiasis problem, as indicated by the reinfection rate of almost 10% at the end of the study.

Adolescent↗

PubMedDate not supplied

Serum antibody response to Opisthorchis viverrini antigen as a marker for opisthorchiasis-associated cholangiocarcinoma.

The liver flukes Opisthorchis viverrini and Clonorchis sinensis chronically infect over 30 million people in south-eastern Asia, resulting in significant morbidity and a predisposition to cholangiocarcinoma (CCA). Liver fluke-associated CCA carries a poor prognosis, partly because it is often detected at a late and advanced stage. The development of improved diagnostic methods, particularly for early CCA, may improve chances of survival and cure. Accordingly, we explored the use of immunological responses to liver fluke antigens as a potential means of identifying individuals at high risk for liver fluke-associated CCA. Serum antibody responses to O. viverrini adult worm homogenate and metacercaria homogenate (MH) were studied using enzyme-linked immunosorbent and immunoblot assays in 65 infected residents of an opisthorchiasis-endemic area in Thailand. Antibody levels correlated with liver ultrasonography (U/S) findings, and immunoblot analysis revealed a 91/93 kDa MH doublet recognized only by sera of individuals with severe liver U/S findings, including CCA. These results suggest that serum antibody responses to liver fluke antigens may be useful in the identification of infected individuals who are at high risk for liver fluke-associated CCA.

Animals↗

PubMedDate not supplied

Artemether-mefloquine combination in multidrug resistant falciparum malaria.

Plasmodium falciparum in Thailand is highly resistant to chloroquine and sulfadoxine/pyrimethamine and there is increasing resistance to the alternative antimalarials, quinine and mefloquine. In eastern Thailand, the cure rates of mefloquine at 750 and 1250 mg were 30% and 55%, respectively. The use of drug combinations may be necessary in areas where drug-resistant parasites exist. 159 male Thai patients in Chantaburi, eastern Thailand, were allocated at random to receive either oral artemether at a single dose of 300 mg on the first day followed by mefloquine 750 mg at 24 h and 500 mg at 30 h (group A), or oral artemether at a single dose of 300 mg on the first day, mefloquine 750 mg at 24 h and placebo at 30 h (group B). The follow-up was on days 1, 2, 7, 14, 21, 28, 35 and 42. Most patients in both groups had a rapid initial response to treatment, parasitaemia being cleared within 24 h and fever cleared within 48 h in both groups. The cure rates were 97% and 90%, respectively, for groups A and B. No serious adverse effect was seen in either group; mild and transient nausea, vomiting and loss of appetite were noted. The adverse effects did not differ between the 2 groups. The results suggested that a single oral dose of artemether (300 mg) can markedly improve the cure rate of mefloquine at a dose of 750 or 1250 mg in multiple drug-resistant falciparum malaria.

Adolescent↗

PubMedDate not supplied

Artemether or artesunate followed by mefloquine as a possible treatment for multidrug resistant falciparum malaria.

Plasmodium falciparum in south-east Asia is highly resistant to chloroquine and sulfadoxine-pyrimethamine. Mefloquine used to be the chemosuppressant drug of choice in areas with chloroquine resistance. However, sensitivity to this drug has recently decreased in Thailand, Cambodia and Myanmar, and there is no suitable single alternative drug. We therefore investigated possible alternative combination therapies for multidrug resistant falciparum malaria. 120 male Thai patients at Makarm Malaria Clinic, Chantaburi, in eastern Thailand were allocated at random to receive either oral artemether (group A) or artesunate (group B) at a single dose of 300 mg on day 1, both followed by mefloquine, 750 and 500 mg at 24 and 30 h, respectively. Follow-up was on days 1, 2, 7, 14, 21, 28, 35 and 42. Patients in both groups had a rapid initial response to treatment; in most cases parasitaemia was cleared within 24 h, and fever was cleared within 24 h in 62% and 76.7% of the patients in groups A and B, respectively. 58 patients in group A and 57 in group B completed follow-up and cure rates were 98% and 97%, respectively. Reinfection could not be excluded for the 3 patients with recrudescences; all were cured with a repeated course of treatment. No serious adverse effect was observed in either group, only mild and transient nausea, vomiting and loss of appetite, with no significant difference between the 2 groups. These results suggest that a single oral dose of 300 mg of either artemether or artesunate followed by 1250 mg of mefloquine in 2 divided doses is effective against multiple drug resistant falciparum malaria. Either regimen can be considered as a suitable 'stand-by' in endemic areas of multiple drug resistant falciparum malaria.

Adolescent↗